Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
